Trastuzumab combined with trimodality treatment does not improve outcomes for patients
Results of the NRG Oncology clinical trial RTOG 1010 indicate that the addition of the monoclonal antibody trastuzumab to neoadjuvant trimodality treatment did not improve disease-free survival (DFS) outcomes for patient ...
Jun 1, 2020
0
0